Brain metastases - Epidemiology and Aetiology
Last review: 01-07-2011This chapter is divided into subchapters and/or paragraphs. In the left column, click on the subchapter and/or paragraph title to view the contents.
- Incidence and relationship with systemic malignancies
- Pathogenesis and pathofysiology
Authorization date and validity
Last review : 01-07-2011
Last authorization : 01-07-2011
The period of validity of the guideline (maximum of 5 years) is being monitored by IKNL. For various reasons, it may be necessary to revise the guideline earlier than intended. Sections of the guideline will be amended in the interim, when required.
Initiative and authorization
Scope and target group
Objective
The guideline covers the processes of diagnosis, treatment, information provision and guidance of adult patients with metastases in the brain originating from solid tumours, thereby focusing on topical clinical problems encountered in daily practice. The guideline's recommendations aim to aid practitioners in their decision-making support when facing these problems. The recommendations are based on the highest available grade of scientific evidence and on consensus within the guideline development group. The guideline provides information on how the recommendations have been reached from the evidence.
The guideline may be used to provide information to patients and offers points of reference for transmural agreements or local protocols to facilitate implementation.
Users
The guideline is intended for all professionals involved in the diagnostics, treatment and guidance of adult patients with brain metastases of solid tumours. These professionals include:
- Primary specialists: neurologists, neurosurgeons, radiotherapists, medical oncologists, pulmonologists, (oncology) nurses, general practitioners, specialists (working) in palliative care
- Supporting specialists: radiologists, pathologists
- Healthcare providers specialised in psychosocial care: social workers, psychologists, psychiatrists and geriatric medicine specialists
Members of the guideline panel
2011:
Chair:
mw. dr. J.M.M. Gijtenbeek, neuroloog, Universitair Medisch Centrum St Radboud, Nijmegen
Other members:
dr. L.V. Beerepoot, medisch oncoloog, St. Elisabeth Ziekenhuis, Tilburg
dr. W. Boogerd, neuroloog, Nederlands Kanker Instituut / Antoni van Leeuwenhoekziekenhuis, Slotervaartziekenhuis, Amsterdam
mw. S. Bossmann, nurse practitioner, Universitair Medisch Centrum St Radboud Nijmegen
mw. dr. M. van Dijk, internist-oncoloog, Maastricht Universitair Medisch Centrum, Maastricht
mw. dr. A.C. Dingemans, longarts, Maastricht Universitair Medisch Centrum, Maastricht
mw. dr. C. van Es, radiotherapeut-oncoloog, Utrecht Universitair Medisch Centrum, Utrecht, niet actief betrokken (is betrokken geweest bij het initiëren van de werkgroep maar kon vanwege onvoorziene omstandigheden niet aan de totstandkoming van de richtlijn meewerken)
dr. A. de Graeff, medisch oncoloog, Utrecht Universitair Medisch Centrum, Utrecht
dr. P.E.J. Hanssens, radiotherapeut-oncoloog, Gamma Knife Centrum, Tilburg
dr. H.F.M. van der Heijden, longarts, Universitair Medisch Centrum St Radboud, Nijmegen
dr. M.A.A.M. Heesters, radiotherapeut-oncoloog Universitair Medisch Centrum Groningen, Groningen
dr. P.A. M. Hofman, neuroradioloog, Maastricht Universitair Medisch Centrum, Maastricht
dr. R.L.H. Jansen, medisch oncoloog, Maastricht Universitair Medisch Centrum, Maastricht, niet actief betrokken
drs. E. Kurt, neurochirurg, Medisch Centrum Alkmaar
dr. F. J. Lagerwaard, radiotherapeut-oncoloog, Vrije Universiteit Medisch Centrum, Amsterdam
mw. prof.dr. J.B. Prins, klinisch psycholoog, Universitair Medisch Centrum St Radboud, Nijmegen
drs. J.H.C. Voormolen, neurochirurg, Leids Universitair Medisch Centrum, Leiden
drs. V.K.Y. Ho, epidemioloog/procesbegeleider, Integraal Kankercentrum Nederland (IKNL), locatie Utrecht
mw. M.L. van de Kar, ambtelijk secretaris, Landelijke Werkgroep Neuro-Oncologie (LWNO), Bussum
Ondersteuning methodologie
mw. dr. M. Brink, epidemioloog, IKNL, locatie Utrecht
drs. J.M. van der Zwan, MSc, epidemiologisch onderzoeker, IKNL, locatie Enschede
Leden werkgroep voorgaande revisie (2004)
dr. R.H. Boerman, neuroloog, Rijnstate Ziekenhuis, Arnhem (voorzitter)
dr. W. Boogerd, neuroloog, Nederlands Kanker Instituut / Antoni van Leeuwenhoekziekenhuis, Slotervaartziekenhuis, Amsterdam
mw. dr. W.M.H. Eijkenboom, radiotherapeut-oncoloog, Daniel den Hoed Kliniek, Rotterdam
dr. P.E.J. Hanssens, radiotherapeut-oncoloog, Dr. Bernard Verbeeten Instituut, Tilburg
dr. R.L.H. Jansen, medisch oncoloog, Academisch Ziekenhuis Maastricht
dr. F. J. Lagerwaard, radiotherapeut-oncoloog, Vrije Universiteit Medisch Centrum, Amsterdam
prof.dr. C.J.A. Punt, inetrnist-oncoloog, Academisch Ziekenhuis Nijmegen
drs. J.H.C. Voormolen, neurochirurg, Leids Universitair Medisch Centrum, Leiden
prof.dr. J.T. Wilmink, neuroradioloog, Academisch Ziekenhuis Maastricht
dr. J.G. Wolbers, neurochirurg, Academisch Ziekenhuis Dijkzigt, Rotterdam
Declaration of interest
|
|||||||||||||||||||||||||||||||||||||||||||||
Method of development
Implementation
Considerations concerning the implementation of the guideline as well as the feasibility of recommendations have been taken into account as much as possible in drafting the revised guideline.
The guideline is summarised and may be consulted in its entirety on http://www.oncoline.nl/. The guideline has been brought to the attention of members of the LWNO, hospitals in the Netherlands, oncology commissions, as well as the scientific and professional associations involved. To further stimulate awareness and implementation of the guideline, regional tumour working groups on neuro-oncology of IKNL were invited to discuss its recommendations.
Given the highly progressive and unfavourable course of the disease, the guideline development group decided not to develop care indicators to measure the level of guideline implementation.